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C/EBP ζBreast cancer is a leading cause of morbidity in women worldwide. neutrophil gelatinase-associated lipocalin
(NGAL), a useful biomarker of ER negative (ER−) breast cancer, promotes local tumor invasion and lymphnode
metastasis. We ﬁrst identiﬁed the distinctive expression of NGAL in two breast cancer cell lines MCF7 and
MDA-MB-231 cells, and then conﬁrmed NGAL as a critical inducer of metastasis. Finally, the transcriptional
factor CCAAT enhancer-binding proteins ζ (C/EBP ζ) was overexpressed inMDA-MB-231 cells. Consistent with
the effect of NGAL knockdown, C/EBP ζ overexpression caused the signiﬁcant changes that could prevent cell
metastasis. C/EBP ζ overexpression induced a strong decrease in NGAL andmatrixmetalloproteinases (MMPs)
expressions as determined by quantitative real time PCR andWestern blotting. To identify the potential role of
C/EBP ζ on regulating of NGAL in breast cancer, we established the dual-luciferase reporter assay for NGAL in
MDA-MB-231 cells cotransfected with C/EBP ζ. Promoter reporter assays determined that C/EBP ζ directly
repressed the human NGAL gene promoter activity by inhibiting the NGAL transcription. Taken together, this
work identiﬁed that the C/EBP ζ overexpression downregulated NGAL to inhibit migration and invasion of
breast cancer, which could be used as a novel strategy for breast cancer therapy.ed lipocalin; EMT, epithelial to
umor suppressor gene; DDIT3,
squamous cell carcinoma; CM,
Ps, Matrix metalloproteinases;
in; 2-MEO, 2-mercaptoethanol
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Breast cancer survival rate falls from 90% for localized to 20% for
metastatic disease [1,2]. The metastasis of tumor cells causes 90% of
human cancer deaths [3]. During the development of most types of
human cancer, including breast carcinoma, primary tumor masses are
always prone to spawn pioneer cells that move out, invade adjacent
tissues, and thence travel to distant sites where they may succeed in
founding new colonies [4]. Chemotherapy is the mainstay treatment
for breast cancer patients with metastatic status. However, many
patients exhibit resistance to chemotherapy that is either inherent or
acquired during treatment [5].
NGAL (also referred to as Lipocalin 2, Lcn2) is a member of the
lipocalin family. Lipocalins are small extracellular proteins that share
the highly conserved structure of an 8-stranded antiparallel β barrel
and have been shown to transport and present ligands, to bind to cell
surface receptors, and to form macromolecular complexes, therebyplaying important roles in cell regulation, proliferation, differentia-
tion, migration, invasion and epithelial to mesenchymal transition
(EMT) [6]. Estrogen exposure is one of the most well recognized risk
factors for breast cancer. The expression of estrogen receptors (ER) in
breast cancer suggests a role for these receptors in its pathogenesis
and therapy [7]. NGAL is among those genes most highly associated
with ER− breast tumors for breast cancer progression, suggesting that
NGAL is a new therapeutic target for the prevention and treatment of
ER− breast cancer [8].
As mentioned above, resistance to chemotherapy is a major
problem facing breast cancer patients. A potential approach instead of
chemotherapy to breast cancer is gene therapy. C/EBP ζ, a transcrip-
tional factor, has been revealed to signiﬁcantly downregulate in
myeloidmalignancies than normal controls [9]. It is a candidate tumor
suppressor gene (TSG) that has been involved in the regulation of
cellular growth and differentiation [10,11]. C/EBP ζ, also named DNA
damage-inducible transcript 3 (DDIT3), belongs to a family of bZIP
regulatory proteins containing two distinct domains: a basic region
that binds to DNA, and an adjacent leucine-zipper region that enables
homo- and hetero-dimerization of C/EBP proteins [12]. Members of
the C/EBP family are known to heterodimerize among themselves,
giving rise to different functional transcriptional complexes. Sequen-
tial expression of different C/EBP members was observed during the
process of cell differentiation [13]. The disruption of these programs is
oncogenic in several cellular contexts [14]. C/EBP ζ is proposed to act
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studies demonstrate that C/EBP ζ expression is essential for the
activation of a number of genes induced in the endoplasmic reticulum
stress response for cell apoptosis [16]. C/EBP ζ has also been
demonstrated to induce a decrease in tumor marker NGAL gene
mRNA expression in human ﬁbrosarcoma cell line HT 1080[17].
Elevated NGAL expression has been shown in different human tumors
including breast [18], lung [19], colorectal [20], ovarian [21],
pancreatic cancer [22], oesophageal squamous cell carcinoma
(ESCC) [23] and hematopoietic malignancies [24]. Based on these
ﬁndings, we hypothesize that C/EBP ζ is potential as a therapeutic
gene for breast cancer treatment, and the overexpression of C/EBP ζ
could downregulate NGAL expression to inhibit the metastasis of
breast carcinoma.
Therefore, in this paper, the potential role of C/EBP ζ on metastasis
was studied in MDA-MB-231 ER− clones, in which C/EBP ζwas stably
overexpressed, thereby resulting in a sustained downregulation of
NGAL. The approach revealed that C/EBP ζ inhibited cell migration and
invasion evidently by counteracting NGAL expression. These ﬁndings
strongly support the concept of gene therapy that manipulation of
C/EBP ζmight be beneﬁcial to the breast cancer therapy depending on
the downregulation of NGAL protein via the transcriptional regulation
on NGAL promoter.
2. Materials and methods
2.1. Cell culture and reagents
HeLa, MCF7, MDA-MB-231 cells were grown in DMEM (Life
Technologies, Rockville, MD), and Jurkat, K562 cells in RPMI 1640 (Life
Technologies). The medium was supplemented with 10% fetal bovine
serum (Life Technologies), 100 U/ml penicillin, and 100 μg/ml
streptomycin (Life Technologies). Cells were grown at 37 °C in a
humid atmosphere with 5% CO2.
The following antibodies were used for Western blotting: anti-β-
actin (Chemicon, USA), anti-human NGAL (R&D Systems, USA), anti-
human NGAL (Abcam, UK), anti-human NGAL (Santa Cruz, USA), and
anti-human C/EBP ζ (DDIT3) (Santa Cruz, USA).
Enhanced Chemiluminescence Reagent Plus (ECL) reagents were
from Santa Cruz Biotechnology (Santa Cruz, USA). Cariporide were
purchased from Sigma (Shanghai, China). FH535 and BAY117082
were purchased from Sigma (Beyotime, Shanghai, China).
2.2. RNA isolation and real time PCR
RNA isolation, DNase treatment, and RT-total RNA were isolated
using Trizol (Invitrogen, Grand Island, NY), treated with DNase I
(Invitrogen, Grand Island, NY), and 2 μg RNA were reverse-transcribed
using Superscript II RT (Invitrogen, Grand Island, NY) following the
manufacturer's instructions in a total volume of 20 μl.
Primers for real time PCR were designed using Primer premier
software 5.0. Human β-actin primers used as an internal control were
5′-CCA CGA AAC TAC CTT CAA CTC C-3′ (forward) and 5′-ACT CGT CAT
ACT CCT GCT TGC T-3′ (reverse; 272 bp). Human NGAL primers were
5′-CAA GGA GCT GAC TTC GGA AC-3′ (forward) and 5′-TAC ACT GGT
CGA TTG GGA CA-3′. Human C/EBP ζ primers were (forward primer)
5′-CAG AAC CAG CAG AGG TCA CA-3′ and (reverse primer) 5′-GCT
GTG CCA CTT TCC TTT C-3′. Real time PCR was performed with
TransGen SYBR Green PCR kit (TransGen Biotech, China) on the ABI
Prism 7500 Fast Sequence Detection System. Thermal cycling
conditions were 95 °C for 10 s, followed by 40 cycles of 5 s at 95 °C,
and 40 s at 60 °C. PCR reactions were performed in a total volume of
20 μl, containing 2 μl of sample cDNA, 0.2 μM of each primer, and the
SYBR Green PCR kit following the manufacturer's instructions. Each
test was ampliﬁed in three different wells in one experiment.2.3. Western blotting
Secreted proteins (secreted NGAL protein included) were sepa-
rated from the conditioned medium (CM) by fast ultraﬁltration using
Amicon® Ultra-15 centrifugal ﬁlter devices (Millipore, USA) accord-
ing to the manufacturer's protocol, intracellular proteins were
isolated by RIPA lysis buffer (RIPA: 150 mM NaCl, 1.0% NP-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris
(pH 8.0)) with protease inhibitors , and 1 mMPMSF (Sigma, USA). The
lysates were cleared using centrifugation at 12,000 rpm for 15 min at
4 °C. Protein samples were completely denatured by boiling for
10 min at 100 °C in the presence of 2% SDS and 10% 2-MEO (2-
mercaptoethanol). The denatured samples were then separated by
10% SDS-PAGE and transferred onto polyvinylidene diﬂuoride
membranes (Millipore, USA). The membranes were blocked for 1 h
with 5% skimmed milk in PBS and then incubated ﬁrst with primary
antibodies and then horseradish peroxidase-conjugated secondary
antibodies for 2 and 1 h, respectively. Speciﬁc proteins were
visualized with enhanced chemiluminescence detection reagent and
determined by densitometric analysis with a Lynx video densitometer
(Biological Vision, Inc., San Mateo, CA).
2.4. Short hairpin RNA-mediated RNA interference studies
Three independent hairpins targeting to NGAL were developed
using software from Ambion. These hairpins were synthesized and
cloned into the eukaryotic vector pSilencer U6 (Ambion, Inc, USA) and
then transfected into MDA-MB-231 cells. Infected cells were selected
by hygromycin 48 h postinfection for at least 2 weeks and stable
cloneswere obtained. Inhibition of NGAL expressionwasmeasured by
quantitative PCR as well as by Western blotting using a rat anti-NGAL
antibody. For RNA interference studies, cells transfected with the
pSilencer vector that expresses a scrambled control siRNA were the
negative control.
2.5. Plasmids for overexpression and promoter studies
Human C/EBP ζwas generated by PCR from a human normal cDNA
library and then cloned into the plasmid pTARGET™/Neo, which was
then used to generate clones encoding the full-length protein (aa 1–
169). A 1221 bp, 500 bp and 236 bp fragments of the human NGAL
promoter region (−1137 to +84; forward primer, 5′-TACTCGAG-
CAAGCAGCACGTAGGCAGAG-3′), (−416 to +84; forward primer, 5′-
AACTCGAGCAGGAAACAGCACATGATCT-3′), (−152 to +84; forward
primer, 5′-TACTCGAGCTGTCTTGCCCAATCCTGAC-3′, and reverse
primer, 5′-ATAGATCTTCAG GGCCGAGGAAGCAGGC-3′) were PCR
ampliﬁed with above corresponding primers, using genomic DNA as
template. The restriction enzyme digested PCR fragmentswere cloned
in Xho I/Bgl II-restricted pGL3-basic (Promega, Madison, WI),
resulting in pGL3-ngal 1208, pGL3-ngal 500, pGL3-ngal 236 plasmids
for luciferase reporter assay. For reporter assay, the fragment of NGAL
promoter from −1137 to −185 with C/EBP ζ potential interaction
sites deleted was PCR ampliﬁed and cloned into the pGL3-promoter
(Promega, USA) as a negative control (designated as pGL3-control),
the primers for PCR were: forward, 5′-TACTCGAGCAAGCAGCACG-
TAGGCAGAG-3′, and reverse, 5′-ATAGATCTACCTCTGGCAGGGA-
CAACG-3′.
2.6. Cell transfection and dual-luciferase reporter assay
MDA-MB-231 cells (1.00×105 cells) were transfected with 500 ng
of the indicated reporter plasmid together with 2.5 ng of the internal
control plasmid phRL-TK using Lipofectamine™ 2000 (Invitrogen,
USA) according to the manufacturer's protocol. Cells were lysed 24 h
after transfection. To analyse the responses to pharmacological
inhibitors of Na+/H+ exchanger 1 (NHE1) selective inhibitor
Fig. 1. Expression patterns of NGAL in various cancer cells. (a) Expression patterns of
NGAL were analyzed by RT-PCR. PCR reactions were performed on templates of cDNA
from different cancer cell lines using a set of primers as in Materials and methods. The
lanes were 1, erythroleukemia K562, 2, acute T cell leukemia Jurkat, 3, uterine cervix
cancer HeLa, 4, breast cancer ER− MDA-MB-231, and 5, breast cancer ER+ MCF7 cell
line. (b) Quantitative real time PCR analysis of NGAL gene expression in MDA-MB-231
and MCF7 cells. (c) CM and intracellular proteins prepared from human breast cancer
cell lines, MDA-MB-231 and MCF7 were subjected to immunoblot analysis with anti-
NGAL antibody. For quantitative real time PCR and Western blotting, β-actin was used
as an internal control.
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with 500 ng of the NGAL reporter plasmids, together with 2.5 ng of
the internal control plasmid phRL-TK. 24 h after transfection, cells
were treated with 4 μg/ml Cariporide for 24 h, and then lysed. The
luciferase activity was measured using the dual-luciferase reporter
system (Promega, USA) according to the manufacturer's instructions.
The transfection efﬁciency was normalized by the Renilla luciferase
activity derived from phRL-TK (Renilla luciferase vectors). The data
shown are the means±SEM. for triplicate samples, representative of
at least three independent experiments.
2.7. Cell migration (wound healing) Assay
Migration of control and NGAL knockdown cells was measured
with the in vitrowound healing assay. Cells were grown for 3 d in six-
well plates. After the cell layer had reached conﬂuence, a wound was
made with a pipette tip followed by extensive washing with serum-
free medium to remove cell debris. For determination of speciﬁc
signaling pathways on the migration of cells, the corresponding
inhibitors were added with cells into the medium, respectively. If
wanted, DMSO (ﬁnal concentration: 0.1%) as vehicle control was
added after wounding. Cells were then cultured as described before
and allowed to migrate into the wound area for up to 36 h at 37 °C. At
the indicated time points, cells were ﬁxed with 2% formaldehyde. The
wound closure was photographed by using a camera (Model
DXM1200, Nikon, Japan) attached to an inverted microscope (Eclipse
TE300, Nikon, Japan).
2.8. Cell invasion assay
Control or NGAL knockdown cells (5×104 per well in 60 μl in
Dulbecco's modiﬁed Eagle's medium , DMEM) were seeded on
Millipore 24-well cell culture inserts (6.5 mm diameter, Merck Milli-
pore, USA) with 8.0 μm pores, precoated with 5 μg BDMatrigel Matrix
(Becton Dickinson, USA) in 45 μL serum-free medium at their upper
surface. For determination of speciﬁc signaling pathways on the
invasion of cells, the corresponding inhibitors were added with cells
into the upper well, respectively. If wanted, DMSO as vehicle control
was added. DMEM with 10% fetal bovine serum was added to the
lower wells to stimulate invasion. Cells were further incubated for
12 h. Thereafter, medium was removed and invading cells were
stained with 0.2% crystal violet in 20% methanol for 30 min at room
temperature. Cells that had migrated through the Matrigel to the
lower surface of the ﬁlter membrane were taken photos under the
microscope (Olympus, Japan). Finally the crystal violet was washed
off from the cells by 33% acetic acid, and then quantiﬁed with a
multiwell plate reader (Biotek Instruments, USA) at a wavelength of
570 nm. Three independent experiments for each sample were
carried out.
2.9. Statistical analyses
All experiments were conducted at least three times and data are
presented as mean±SEM. Statistical analysis was performed with the
SPSS software package (version 13.0; SPSS). Two-tailed P values b0.05
were considered statistically signiﬁcant.
3. Results
3.1. Expression of NGAL in various cell lines
NGAL has been reported to be associated with various cancers. We
detected NGAL message on mRNA level in several human cancer cell
lines including erythroleukemia K562, acute T cell leukemia Jurkat,
uterine cervix cancer HeLa, breast cancer ER− MDA-MB-231, and ER
positive (ER+) MCF7 cells by reverse transcription (RT) PCR analysis(Fig. 1a). To observe the distinctive expression of NGAL between
MDA-MB-231 ER− and MCF7 ER+ cells, NGAL levels were ﬁnally
examined by quantitative real time PCR and Western blotting.
Quantitative PCR analysis revealed that MDA-MB-231 cells expressed
a relatively high level of NGAL, but a very low level was detected in
MCF7 cell line compared with the internal control β-actin. The change
of NGAL mRNA expression is approximate to 48-fold (Fig. 1b). Results
of Western blotting also showed the distinctive signals for the bands
of NGAL in these two breast cancer cell lines. The results suggest the
distinctive expression of NGAL in different types of breast cancers on
the quantity. NGAL level is much higher in MDA-MB-231 than in
MCF7 cells, correlating with the invasive status of cell line. Given the
fact that NGAL is secreted from the carcinoma cells into the
conditioned medium (CM), we also detected the CM NGAL signals
by Western blotting after total secreted proteins were concentrated
by Millipore fast ultraﬁltration devices. Much stronger signals for CM
NGAL were detected, even the volume of sampling for Western
blotting from CM is 30 times less than that from cell lysate, on
condition that both of these protein samples were collected by equal
volume of sampling buffer (Fig. 1c).These results also suggest the fact
that secreted protein is the mainly existent form for NGAL of MDA-
MB-231 cells.
3.2. NGAL knockdown inhibits migration and invasion of MDA-MB-231
cells
To conﬁrm the NGAL-mediated effects on metastasis, NGAL was
silenced with three different shRNA plasmids in MDA-MB-231 cells,
which express the higher level of NGAL and exhibit a more
pronounced metastasis phenotype. Markedly reduced CM and
intracellular NGAL levels were observed after transfection with the
more effective shRNA1 and 2 in both mRNA and protein levels (Fig. 2a
and b). The classic phenotype of metastasis breast cancer cell line with
an elongated morphology and more evenly distribution across the
Fig. 2. NGAL silencing reduces metastasis of MDA-MB-231 cells. (a) Quantitative real time PCR analysis of NGAL gene expression in MDA-MB-231 cells transfected with NGAL short
hairpin RNA plasmids 1 and 2 (shRNA1 and 2). (b) Downregulation of NGAL protein after NGAL shRNA plasmids transfection. (c) Morphological changes of MDA-MB-231 cells after
NGAL shRNA plasmids transfection (original magniﬁcation 200×). (d) Quantitative real time PCR analysis of MMP2, 9, 14 gene expression in MDA-MB-231 cells transfected with
NGAL shRNA 2. (e) Protein levels of MMP9 after NGAL shRNA 2 transfection. (f)Representative pictures of wound healing assay for cell migration after NGAL shRNA 2 transfection.
(original magniﬁcation 200×) (g) Representative pictures of transwell assay for cell invasion after NGAL shRNA transfection (original magniﬁcation 100×). (h) Invasion of MDA-MB-
231 cells after NGAL shRNA transfection. Data were collected from 5 wells. **, Pb0.01, ***, Pb0.001, compared with the control. For quantitative real time PCR andWestern blotting,
β-actin was used as an internal control. Cells transfected with a scramble vector was used as a control for shRNA plasmid mediated RNA interference experiments. Photos of all cells
were taken by an inverted microscope as described under Materials and methods.
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MB-231 cells. NGAL knockdown cells transfected with shRNA1 and
shRNA2 exhibited cobblestone-like appearance and strong cell-cell
adhesion that is typical of epithelial phenotype like that of MCF7 as
expected. And the classic phenotypic changes to the retracted and
rounded appearance were also detected in NGAL knockdown clones
(Fig. 2c).
Degradation of extracellular matrix and vascular basement
membrane is one of the ﬁrst steps required for breast cancer cell to
invade. Matrix metalloproteinases (MMPs) have been strongly
implicated in this step. MMP2, MMP9, and MMP14 (MT1-MMP) are
among the major proteinases that have such a role [25,26]. We nextexamined the expression status of these key MMPs in the NGAL
silenced cell clones. These classic MMPs were all markedly decreased
as shown by quantitative PCR analysis (Fig. 2d). Western blotting
conﬁrmed the decreased expression of MMP9 corresponding to the
NGAL knockdown (Fig. 2e).
A key feature of cells that have higher expression of NGAL and
MMPs is their increasedmigration and invasion. Controls of MDA-MB-
231 cells with higher NGAL expression exhibited markedly higher
levels of migration and invasion, in contrast to NGAL knockdown cells
by shRNA1 and 2 in which fewer migration and invasion were
observed by the wound healing assay (Fig. 2f) and cell invasion assay
(Fig. 2g and h), respectively.
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changes and decreased expression of MMPs, and then inhibits the
migration and invasion of MDA-MB-231 cells.
3.3. C/EBP ζ targets to NGAL to inhibit migration and invasion of MDA-
MB-231 cells
To test whether overexpression of C/EBP ζ is sufﬁcient to inhibit
the migration and invasion of MDA-MB-231 cells, we transfected
MDA-MB-231 cells with C/EBP ζ plasmid and observed a dramatic
increased expression of C/EBP ζ in protein level. We then determined
whether C/EBP ζ overexpression regulated the expression of NGAL.
The result showed that overexpression of C/EBP ζ dramatically
neglected the NGAL expression both in mRNA and protein levels
(Fig. 3a and b). We ﬁnally evaluated whether C/EBP ζ protein had an
impact on cell morphology. Compared to the control, the over-
expression of C/EBP ζ resulted in dramatic phenotypic changes and
condensation at the cell periphery, with retracted, rounded size and
reduced pseudopod-like structure (Fig. 3c). Moreover, we also found
that induction of C/EBP ζ expression resulted in a decrease in the three
MMPs mRNA (MMP2, 9, 14, Fig. 3d) expressions, and the reduced
expression of MMP9was ﬁnally veriﬁed byWestern blotting (Fig. 3e).
As expected, overexpression of C/EBP ζ led to a signiﬁcant reduction in
cell migration capacity (Fig. 3f) and more than a half decrease in the
cell invasiveness (Fig. 3g and h).These data indicate that, in contrast to
NGAL, C/EBP ζ is an anti-migratory and anti-invasive factor for ER−
cells. Overexpression of C/EBP ζ could dramatically decrease the
expression of metastasis accelerators NGAL and MMPs expressions,
and then ﬁnally inhibit the migration and invasion of MDA-MB-231
cells.
Lastly, there must be an emphasis on that, to determine C/EBP ζ
regulation of the NGAL at the transcription levels, we performed
quantitative real time PCR and found that C/EBP ζ decreased mRNA
expression of NGAL (Fig. 3a). This result suggests that C/EBP ζ regulate
NGAL mainly at the transcriptional level for our further study.
3.4. Inhibition of NHE1 reduces cell migration and invasion depending on
C/EBP ζ elevation-mediated NGAL downregulation
NHE1 in the regulation of the intracellular pH (pHi) and
extracellular pH (pHe) is necessary for the metastasis of tumor cells
[27]. We next sought to determine whether inhibition of NHE1 was
involved in the process of cell migration and invasion that was
mediated by C/EBP ζ and NGAL. Cariporide, a selective inhibitor of
NHE1 that could block the efﬂux of H+ to achieve intracellular
acidiﬁcation, was used to detect the effect of NHE1 inhibition on the
expressions NGAL and C/EBP ζ. A decrease of NGAL mRNA synthesis
was observed when the cells were incubated with Cariporide and
resulted in a decrease of NGAL protein both in the cell context and
conditioned medium at 24 h relative to that measured from control
cells at the same time points(Fig. 4a and c). In contrast, an increase of
C/EBP ζ was detected under the same treatment conditions by
Cariporide both in the mRNA and protein levels(Fig. 4b and c). As our
prediction, this process was strongly accompanied with signiﬁcantly
decreased migration and invasion abilities of MDA-MB-231 cells
(Fig. 4d–f). Furthermore, treatment with Cariporide also down-
regulated MMP2, MMP9 and MMP14 mRNA expressions. As the
experiment of Live Cell Station, we detected the morphological
changes of cell to a retracted and rounded size treated with Cariporide
for 24 h (data was not shown). Though the limited capacity of
Cariporide on metastasis was not so evident compared with that of
the C/EBP ζ overexpression or NGAL knockdown, these results indeed
indicate that the effects of NHE1 inhibition on cell migration and
invasion are at least partly by facilitating the regulation of NGAL
mediated by C/EBP ζ. Thus Cariporide could contribute to the
inhibitory effects of C/EBP ζ on cell metastasis by increasing theendogenous expression of C/EBP ζ and the subsequent downregula-
tion of NGAL expression.3.5. NGAL is a direct transcriptional target of C/EBP ζ via special
functional promoter fragments
As shown in Fig. 3a, cells overexpressed C/EBP ζ display more than
4-fold decreased expression of NGAL mRNA compared with the
control. These results suggest that C/EBP ζ probably regulate NGAL at
the transcription level. As reported before on interleukin (IL6 and 8)
expression, C/EBP ζ changes the binding properties of C/EBP β to DNA
by forming a heterodimers and also inhibits the effect of NF-κB site
mediated through interactions with some special factor [17,28]. We
doubt that if the transcription factor C/EBP ζ regulates NGAL mRNA in
this way. To verify our speculation, we ﬁnally performed promoter
reporter assay with a luciferase reporter plasmid under control of
different fragments of NGAL 5′-upstream region.We ﬁrst analyzed the
NGAL promoter and identiﬁed some potential C/EBP and NF-κB
binding sites. As reported before, inspection of the sequence between
−183 to −153 revealed a putative sequence 5′-GGGAATGTCC-3′
(−180 to −171) with homology (7 of 8 nt match) to the NF-κB
consensus sequence 5′-GGG(A/G)NNT(C/T)CC-3′, and two putative
C/EBP sites at −148 to −139 (C/EBP-1, 5′-CTTGCCCAAT-3′) and
−130 to-121 (C/EBP-2, 5′-GGTGCAGAAA-3′) with 8 and 6 bases of 10
matching the C/EBP consensus sequence (5′-(A/G)TTGCG(T/C)AA
(T/C)-3′), respectively.
Three fragments of NGAL promoters were constructed: −1137 to
+84(pGL3-1221), −416 to +84 (pGL3-500, including NF-κB and
C/EBPs), and −152 to 84 (pGL-236, including C/EBPs) (Fig. 5a). We
ﬁnally determined whether these regions of NGAL promoter were
effective for its basic transcriptional induction. Dual-luciferase
reporter assay showed that the basal expression of the promoter
was remained 85% for pGL3-500 when truncating from −1137 to
−415, and then remained 26% for pGL3-236 until the region between
−416 and −151 was deleted. The result indicates that cis-elements
in these two fragments−416 to−153 and−152 to +84 are mainly
in charge of the NGAL effective transcription (Fig. 5b).
Our focus was, however, on the elements responsible for the
transcriptional induction by C/EBP ζ. Therefore, we next measured the
luciferase activity of cells transfected with C/EBP ζ. Compared to each
own control, genetically modiﬁedMDA-MB-231 cells transfected with
C/EBP ζ showed decreased luciferase activities for different 5′
deletions of the NGAL promoter. An ~8-fold decreased induction of
luciferase activity was found for the pGL3-1221 with fragment of
−1137 to +84, a ~7-fold decrease was measured for the pGL3-500
(−416 to+84), and a ~2.5-fold reductionwas observed for pGL3-236
(−152 to 84) (Fig. 5c), whereas no decreased induction by C/EBP ζ
was observed for the pGL3-control plasmid with the NGAL promoter
fragment from −1137 to −185, which was lack of NF-κB and C/EBP
sites (Fig. 5d). These results demonstrate that cis-elements between
−416 to −153 and −153 to +84 are mainly in charge of the
decreased NGAL synthesis mediated by C/EBP ζ overexpression.
The effect of NHE1 selective inhibitor Cariporide on NGAL
promoter activity was also tested by dual-luciferase reporter assay.
Treated with Cariporide for 24 hours, in contrast to C/EBP ζ elevation,
we detected a decreased promoter activity of NGAL: ~8-fold for pGL3-
1221, ~7.5-fold for pGL3-500 and ~5.5-fold for pGL3-236 (Fig. 5e),
whereas no decreased induction by C/EBP ζ was observed for the
pGL3-control plasmidwith the NGAL promoter fragment from−1137
to−185 under the same treatment conditions by Cariporide (Fig. 5f).
Taken together, the observed effects of luciferase enzyme activity
indicate that C/EBP ζ regulates NGAL transcriptional activity by
binding to the special cis-element in the NGAL promoter. And the
activation of NHE1 also participates in the process of C/EBP ζmediated
NGAL transcriptional activity.
Fig. 3. Overexpression of C/EBP ζ inhibits metastasis of MDA-MB-231 cell. (a) Quantitative real time PCR analysis of NGAL gene expression in MDA-MB-231 cells transfected with
C/EBP ζ plasmid. (b) Protein levels of C/EBP ζ and NGAL expression in MDA-MB-231 cell with C/EBP ζ overexpression were detected byWestern blotting. (c) Morphological changes
of MDA-MB-231 cells after C/EBP ζ overexpression (original magniﬁcation 200×). (d) Quantitative real time PCR analysis of MMP2, 9, 14 gene expression in MDA-MB-231 cells
transfected with C/EBP ζ plasmid. (e) Protein levels of MMP9 after C/EBP ζ plasmid transfection. (f) Representative pictures of wound healing assay for cell migration after C/EBP ζ
overexpression (original magniﬁcation 200×). (g) Representative pictures of transwell assay for cell invasion after C/EBP ζ overexpression (original magniﬁcation 100×).
(h) Invasion of MDA-MB-231 cells after C/EBP ζ overexpression. Data were collected from 5 wells. For quantitative real time PCR and Western blotting, β-actin was used as an
internal control. For all the above experiments, cells transfected with a control vector was used as a control. Photos of all cells were taken by an inverted microscope as described
under Materials and methods. Data were collected from at least three independent experiments. **, Pb0.01, ***, Pb0.001, compared with control.
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invasion
Here our study demonstrated that NF-κB pathway might be
involved in NGAL regulation, and previous report indicated that Wnt
signaling pathway was also involved in NGAL expression. Toinvestigate the signaling pathways involved in NGAL-mediated cell
invasion, inhibitors for these two signaling pathways were used to
assay their effects on NGAL expression and NGAL-mediated cell
invasion. We inactivated the Wnt and NF-κB pathways with FH535
and BAY117082 respectively. As shown in Fig. 6a and b, these two
inhibitors could signiﬁcantly decrease NGAL protein expression both
Fig. 4. Inhibition of NHE1 by Cariporide reduces cell metastasis partly depending on C/EBP ζ via NGAL downregulation (a) Quantitative real time PCR analysis of NGAL gene
expression in MDA-MB-231 cells after treated with Cariporide. (b) Quantitative real time PCR analysis of C/EBP ζ gene expression in MDA-MB-231 cells after treated with Cariporide.
(c) Protein levels of C/EBP ζ and NGAL after cell treated with of Cariporide. (d) Representative pictures of wound healing assay for cell migration after treated with Cariporide
(original magniﬁcation 200×). (e) Representative pictures of transwell assay for cell invasion after treated with Cariporide (original magniﬁcation 100×). (f) Invasion of MDA-MB-
231 cells by the treatment of Cariporide. Data were collected from 5 wells. For quantitative real time PCR and Western blotting, β-actin was used as an internal control. Data were
collected from at least three independent experiments. *, Pb0.05; **, Pb0.01, comparedwith control. Cariporidewith a few different concentrations were used for these experiments,
the results shown here only for 4 mg/l.
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Finally, we evaluated whether signaling through the Wnt and NF-κB
pathways impacted cell invasion. Consistent with the decreased NGAL
expression, the results showed that Wnt (FH535) and NF-κB
(BAY117082) speciﬁc inhibitor reduced the invasion of MDA-MB-
231 cells (Fig. 6c–f) similar to the effects induced by C/EBP ζ
overexpression. However, inhibition of these two pathways was
observed to be more signiﬁcantly diminished the cell invasion,
suggesting that some other molecules regulated by these two
signaling pathways involved in MDA-MB-231 cell metastasis process.
These studies conﬁrm our result that NF-κB pathway participate in
NGAL-mediated cell migration and invasion, moreover it also
suggested that NGAL-mediated tumormetastasis was regulated partly
by Wnt signaling, a usual active pathway in breast cancer.
4. Discussion
Breast cancer is a leading cause of morbidity in womenworldwide.
Invasive cancer culminating in metastasis is the leading cause of thesecancer-associated deaths. NGAL expression has been reported to be
strongly correlated with a negative ER status, which is consistent with
several global gene expression proﬁling studies [2,29]. The protein
contributes to the aggressive behavior and mesenchymal phenotype
of MDA-MB-231 cells, suggesting that NGAL is a potential therapeutic
target for ER− breast cancers. Human NGAL (neutrophil gelatinase-
associated lipocalin, also referred to as lipocalin 2, Lcn2) is a member
of the lipocalin family of small secreted proteins. It is up-regulated in a
number of pathological conditions, including cancers. In the past,
scientists had devoted a lot of work to the quantitative difference of
NGAL expression. Consistent with previous reports, we have detected
that MDA-MB-231 cell indeed bears a greatly higher expression of
NGAL than MCF7 cell line. As the result shows much stronger signals
from Western blotting for CM NGAL were detected, even the volume
of sampling from conditioned medium is 30 times less than that from
cell context, on condition that both of these protein samples were
collected by equal volume of sampling buffer, suggesting that secreted
protein is the mainly existent form for NGAL fromMDA-MB-231 cells.
However, different distributions as well as molecular forms of NGAL
Fig. 5. C/EBP ζ regulates NGAL expression by special functional promoter fragments of NGAL gene (a) Cartoon depicting the NGAL promoter constructs used. (b) Luciferase assays of
the promoter fragments in MDA-MB-231 cells for NGAL basic expression. (c) Luciferase assays of the promoter fragments in MDA-MB-231 cells with C/EBP ζ overexpression for
NGAL expression. (d) Luciferase reporter assays of the promoter fragments without potential C/EBP interacting sites (pGL3-control plasmid) in MDA-MB-231 cells with C/EBP ζ
overexpression for NGAL expression. (e) Luciferase assays of the promoter fragments in MDA-MB-231 cells with Cariporide treatment for NGAL expression. (f) Luciferase reporter
assays of the promoter fragments without potential C/EBP ζ interacting sites (pGL3-control) in MDA-MB-231 cells with Cariporide treatment for NGAL expression. Graphed values
were obtained by normalizing measured ﬁreﬂy luciferase activity by protein quantitation for sampling and renilla luciferase activity from the contransfected vector phRL-TK. Error
bars represent 95% conﬁdence intervals. Data are pooled from three independent experiments performed in biological triplicates. *, Pb0.05; **, Pb0.01, ***, Pb0.001, compared with
control.
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underlying these different existent forms of NGAL still remain
unknown in cancers, so further studies are still needed to elucidate
these issues.
To ensure the NGAL-mediated effects on metastasis, NGAL was
silenced in MDA-MB-231 cells, which express the greatly higher level
of NGAL and exhibit a more pronounced metastasis phenotype.
Downregulation of NGAL showed an effective inhibition of tumor
migration and invasion. Results implicate that NGAL is an effective
therapeutic target for ER− breast cancer. Our ﬁndings are consistent
with a recent report describing the strong correlation between NGAL
levels in primary breast cancer and ER negative status, poor histologic
grade, and lymph node metastasis, and provide the evidence bydirectly detecting migration/invasion velocity and morphological
change of tumor cells.
C/EBP ζ encodes a transcription factor belonging to the CCAAT/
enhancer binding protein (C/EBP) family. It is expressed ubiqui-
tously and can be induced by a wide variety of treatments such as
DNA lesion, hypoglycaemia, radiation and cellular stress. The
protein was ﬁrst identiﬁed as a central factor in endoplasmatic
reticulum stress and DNA damage response. The level of C/EBP ζ
transcript in myeloid malignancies CML patients is signiﬁcantly
lower than that in controls. Recent evidence suggests that C/EBP ζ is
a key molecule whose downregulation may be a prerequisite for
cellular transformation induced by oncogenes such as Ras and
c-myc [30,31]. Together, these results implicate that expression of
Fig. 6. Inhibitors for Wnt and NF-κB signaling pathways reduce NGAL-mediated cell metastasis. (a) Protein levels of NGAL after cell treated with BAY117082. (b) Protein levels of
NGAL after cells treated with FH535. For Western blotting, β-actin was used as an internal control. (c) Representative pictures of Transwell assay for cell invasion after treated with
BAY117082. (d) Representative pictures of Transwell assay for cell invasion after treated with FH535. (e) Invasion of MDA-MB-231 cells by the treatment of BAY117082. (f) Invasion
of MDA-MB-231 cells by the treatment of FH535. Data are collected from 5 wells. **, Pb0.01, compared with control. Cells treated with the equal quantity of DMSO for dissolving
inhibitors were used as a control. Photos of all cells were taken by an inverted microscope (original magniﬁcation 100×) as described under Materials and methods.
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cell. However, the data is still lacking about the effect of C/EBP ζ on
breast cancer. We ﬁnally introduce C/EBP ζ in MDA-MB-231 cell.
The data presented here suggest that C/EBP ζ plays a signiﬁcant
inhibitory role in NGAL expression, its upregulation contributes to
the reduction of cell migration and invasion by downregulating
NGAL and MMPs.
A large body of researches implicates a role for C/EBP ζ in the
regulation of NGAL expression. The earlier investigators found that
C/EBP ζ functions as negative regulator of C/EBP β-dependent IL-6
expression in B cells [28]. C/EBP ζ is proposed to act as a dominant
negative inhibitor of other C/EBPs by forming C/EBPζ:C/EBP hetero-
dimers. C/EBPζ:C/EBP heterodimers fail to bind several known C/EBP
sites in vitro. The NGAL promoter contains a putative C/EBP-binding
site, suggesting that interruption of the classical C/EBP transactivators
by C/EBP ζ could mediate NGAL expression by the transcriptional
regulation via NGAL promoter. However, other probability still exists.
In contrast to this conventional model of C/EBPζ:C/EBP activity, an
earlier experiments showed that a deletion mutated C/EBPζ lacking
the leucine-zipper dimerization domain still caused downregulation
of IL8[17]. Instead, the research declared that part of C/EBP ζ's
inhibitory effect may be mediated through interactions with a factorbinding to the NF-κB site as mutation of the NF-κB site strongly
counteracted the inhibitory effects of C/EBP ζ on IL8 transcription.
NF-κB has been demonstrated to contribute to cell survival by
controlling iron uptake via NGAL in thyroid tumor [32]. Our result
of luciferase reporter assay indicates that cis-elements in these two
fragments −416 to +84 and −152 to +84 are mainly in charge of
the NGAL effective transcription. Inspection of the sequence between
−183 and −153 revealed a putative sequence 5′-GGGAATGTCC-3′
(−180 to −171) with homology (7 of 8 nt match) to the NF-κB
consensus sequence 5′-GGG(A/G)NNT(C/T)CC-3′, and two putative
C/EBP sites at −148 to −139 (C/EBP-1, 5′-CTTGCCCAAT-3′) and
−130 to-121; C/EBP-2, 5′-GGTGCAGAAA-3′) with 8 and 6 bases of 10
matching the C/EBP consensus sequence (5′-(A/G)TTGCG(T/C)AA
(T/C)-3′) respectively. Taken all together, this study shows that the
both of C/EBP and NF-κB sites in the promoter of NGAL might be
linked to the C/EBP ζ mediated NGAL knockdown. The results were
consistent with a previous report of IκB-ζ which acted as an essential
transcriptional activator by forming a complex with NF-κB on
promoters harbouring the NF-κB- and C/EBP-binding sites, upon
stimulation of TLRs or IL-1 receptor [33].
Cellular alkalinization, a phenotype common to all tumor cells, is
the consequence of the stimulation of a member of the Na+/H+
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regulated by loss of NHE1 activity and decreased pHi, cells with ion
translocation-defective NHE1 had a marked decrease in MMP9 and
NGAL expression but a dramatic increase in C/EBP ζ expression [35].
Consistent with previous report, we found that the cell membrane
NHE1 was involved in cell migration and invasion [36]. Finally, we
demonstrated that inactivation of NHE1 by the selective inhibitor
Cariporide inhibited the expression of NGAL, accompanied with the
upregulation of C/EBP ζ. NGAL covalently bound to MMP9 and
protects MMP9 from degradation may partly interpret the reason of
MMP9 downregulation in our experiments [37]. But the decrease of
other MMPs (MMPs 2 and 14) might be a result of EMT loss caused by
NGAL downregulation. Moreover, NHE1 probably regulates cell
migration and invasion in several pathways. The alkaline pHi caused
by NHE1 activation has been recently demonstrated to be associated
with the expression level of vascular endothelial growth factor
(VEGF), which plays an important role in the induction of neovascu-
larization, thereby promoting tumor growth and metastatic potential,
both in solid and hematologic malignancies [38,39]. NHE1 also
participates in the regulation of the actin cytoskeleton dynamics
necessary for the adhesion and pseudopodial protrusion of motile,
invasive tumor cells [40]. NGAL has been reported to be involved in
these processes, including tumor migration and invasion, but whether
downregulation of NGAL caused by NHE1 inhibition mediates MDA-
MB-231 cellmigration and invasion through theseways still needs to be
further studied. Here our results implicate that the selective inhibitor of
NHE1, Cariporide, [41], could be used to promote the inhibitory effect of
the C/EBP ζ on cell metastasis partly by down regulating NGAL and
MMPs by means of increasing the endogenous expression of C/EBP ζ.
The initiation and progression of breast tumors are driven by
various inherited and acquired genetic changes that are reﬂected in
phenotypic alterations [42,43]. Wnt signaling pathway is also
demonstrated involved in NGAL-mediated tumor metastasis, suggest-
ing a complexity of network thatmultiple signaling pathways regulate
cancer progression. Our data suggest that C/EBP ζ inhibits cell
migration and invasion in human breast cancer through down-
regulation of NGAL and MMPs. C/EBP ζ regulates NGAL expression
depending on the transcriptional regulation via speciﬁc sites of NGAL
promoter. The selective NHE1 inhibitor Cariporide facilitates this
process by decreasing the NGAL expression via upregulating the
endogenous C/EBP ζ. Association of increased C/EBP ζwith a decreased
NGAL expression by NHE1 inhibitor Cariporide also contributes to
inhibition of cellmigration and invasion. Thus, targeting to C/EBP ζ and
combined with NHE1 selective inhibitor Cariporide could provide a
coming effective strategy for treating ER− breast cancer.
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